NewAmsterdam Pharma vs Viridian Therapeutics, Inc.\DE
NAMS and VRDN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NAMS and VRDN compare
Viridian Therapeutics, Inc.\DE grew revenue faster over the last twelve months (23220% versus −88.9% for NewAmsterdam Pharma).
Viridian Therapeutics, Inc.\DE keeps more of each dollar of sales as profit, with a net margin of −544% compared with −3644% at NewAmsterdam Pharma.
NewAmsterdam Pharma scores higher on the StockData Score (6 against 4 for Viridian Therapeutics, Inc.\DE), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NAMS | VRDN |
|---|---|---|
| Size and price | ||
| Market cap | – | $3.4B |
| Share price | $19.39 | $30.06 |
| Change, 1 year | −49.4% | 4.5% |
| Change, 5 years | 98.1% | 64.3% |
| Beta (5Y) | 1.57 | −0.13 |
| Employees | 100 | 252 |
| StockData Score | ||
| Total score | 6 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 47.9× |
| P/B | – | 5.1× |
| FCF yield | – | −9.8% |
| Fair value | – | $8.47 |
| Margin of safety | – | −255% |
| Growth | ||
| Revenue growth (TTM) | −88.9% | 23220% (better) |
| Revenue growth, 5Y average | – | 132% |
| Profitability | ||
| Operating margin | −3432% | −570% (better) |
| Net margin | −3644% | −544% (better) |
| FCF margin | −2018% | −471% (better) |
| Return on equity | −36.8% (better) | −65.7% |
| Return on invested capital | −1046% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −26.0× |
| Current ratio | 9.03 | 16.95 (better) |
| Altman Z-score | – | 2.65 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −1.7% |
| Shareholder yield | – | −1.7% |
| Ownership | ||
| Held by institutions | – | 120% |
| Held by insiders | 22.0% | 21.8% |
| Insider net buying, 12 months | −$63.0M | $19.6M (better) |
| Short interest, % of float | – | 19.2% |
Go deeper
- NAMS stock overview
- NAMS income statement
- NAMS valuation and score
- VRDN stock overview
- VRDN income statement
- VRDN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.